Shares of Indivior PLC (LON:INDV) have been given a consensus recommendation of “Buy” by the seven brokerages that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is GBX 419.29 ($5.46).
A number of research analysts have recently commented on the stock. Numis Securities Ltd restated a “buy” rating and issued a GBX 490 ($6.38) price target on shares of Indivior PLC in a report on Tuesday, July 11th. Stifel Nicolaus restated a “buy” rating and issued a GBX 500 ($6.51) price target on shares of Indivior PLC in a report on Tuesday, April 4th. Finally, Jefferies Group LLC restated a “buy” rating and issued a GBX 490 ($6.38) price target on shares of Indivior PLC in a report on Wednesday, June 7th.
Indivior PLC (LON:INDV) traded up 0.44% during midday trading on Monday, hitting GBX 317.20. 1,011,305 shares of the stock traded hands. Indivior PLC has a 52-week low of GBX 261.30 and a 52-week high of GBX 382.30. The company’s market cap is GBX 2.29 billion. The firm’s 50-day moving average is GBX 318.67 and its 200-day moving average is GBX 324.74.
WARNING: “Indivior PLC (LON:INDV) Given Average Recommendation of “Buy” by Analysts” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/07/25/indivior-plc-lonindv-given-average-recommendation-of-buy-by-analysts-updated.html.
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.